Guggenheim Downgrades Regeneron Pharma (REGN) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mail
Get Alerts REGN Hot Sheet
Price: $927.89 +13.33%
Rating Summary:
30 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Rating Summary:
30 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Join SI Premium – FREE
Guggenheim analyst Yatin Suneja downgraded Regeneron Pharma (NASDAQ: REGN) from Buy to Neutral with a price target of $425.00 (from $466.00).
For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.
Shares of Regeneron Pharma closed at $422.51 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Regeneron Pharma (REGN) PT Raised to $875 at Baird
- Alnylam Pharmaceuticals (ALNY) PT Lowered to $350 at Freedom Broker
- Boot Barn (BOOT) PT Lowered to $175 at Jefferies, 'We recommend buying BOOT'
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesRelated Entities
GuggenheimSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
